D-0761-2023 Class II Terminated
FDA drug recall D-0761-2023 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on May 9, 2023 and is designated Class II. Reason for recall: Failed Dissolution Specifications; during stability testing The recall status is terminated (terminated Feb 27, 2024). Affected quantity: 5,344 Bottles.
Recall details
- Product Type
- Drugs
- Report Date
- May 31, 2023
- Initiation Date
- May 9, 2023
- Termination Date
- Feb 27, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 5,344 Bottles
Product description
buPROPrion Hydrochloride Extended-Release Tablets, USP (SR) 150 mg, 60 Tablets, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ, Manufactured by: Sun Pharmaceutical Industries Limited, Gujrat, India, NDC 47335-737-86
Reason for recall
Failed Dissolution Specifications; during stability testing
Distribution pattern
Nationwide in the U.S.A
Code information
Lots: HAC2240A, Exp 05/2023; HAC3162A, Exp 07/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0761-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026